TECN Stock Overview
Tecan Group AG provides laboratory instruments and solutions for pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories.
Tecan Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CHF287.60|
|52 Week High||CHF602.00|
|52 Week Low||CHF264.60|
|1 Month Change||-8.47%|
|3 Month Change||-23.18%|
|1 Year Change||-40.06%|
|3 Year Change||11.99%|
|5 Year Change||60.31%|
|Change since IPO||513.22%|
Recent News & Updates
Should You Be Adding Tecan Group (VTX:TECN) To Your Watchlist Today?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
|TECN||CH Life Sciences||CH Market|
Return vs Industry: TECN underperformed the Swiss Life Sciences industry which returned -24.7% over the past year.
Return vs Market: TECN underperformed the Swiss Market which returned -12.4% over the past year.
|TECN Average Weekly Movement||6.5%|
|Life Sciences Industry Average Movement||6.5%|
|Market Average Movement||4.6%|
|10% most volatile stocks in CH Market||7.6%|
|10% least volatile stocks in CH Market||2.4%|
Stable Share Price: TECN is more volatile than 75% of Swiss stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: TECN's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
|1980||3,291||Achim von Leoprechting||https://www.tecan.com|
Tecan Group AG provides laboratory instruments and solutions for pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. It operates through Life Sciences Business and Partnering Business segments. The company offers liquid handling and automation, microplate readers and washers, consumables, NGS reagents, immunoassays and microbodies, and software; Tecan Laberwax, an automation solution; Resolvex, a smart sample preparation solution for use in genomics, synthetic biology, drug discovery, analytical chemistry, cell biology, protein science, applied markets, and ELISA solutions.
Tecan Group Fundamentals Summary
|TECN fundamental statistics|
Is TECN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TECN income statement (TTM)|
|Cost of Revenue||CHF538.05m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Aug 17, 2022
|Earnings per share (EPS)||9.56|
|Net Profit Margin||12.85%|
How did TECN perform over the long term?See historical performance and comparison
1.0%Current Dividend Yield
Is TECN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for TECN?
Other financial metrics that can be useful for relative valuation.
|What is TECN's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does TECN's PE Ratio compare to its peers?
|TECN PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
BANB Bachem Holding
SFZN Siegfried Holding
PPGN PolyPeptide Group
SKAN SKAN Group
TECN Tecan Group
Price-To-Earnings vs Peers: TECN is good value based on its Price-To-Earnings Ratio (30.1x) compared to the peer average (59x).
Price to Earnings Ratio vs Industry
How does TECN's PE Ratio compare vs other companies in the European Life Sciences Industry?
Price-To-Earnings vs Industry: TECN is good value based on its Price-To-Earnings Ratio (30.1x) compared to the Swiss Life Sciences industry average (46.2x)
Price to Earnings Ratio vs Fair Ratio
What is TECN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||30.1x|
|Fair PE Ratio||35.3x|
Price-To-Earnings vs Fair Ratio: TECN is good value based on its Price-To-Earnings Ratio (30.1x) compared to the estimated Fair Price-To-Earnings Ratio (35.3x).
Share Price vs Fair Value
What is the Fair Price of TECN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: TECN (CHF287.6) is trading below our estimate of fair value (CHF487.74)
Significantly Below Fair Value: TECN is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: TECN is poor value based on its PEG Ratio (2.3x)
Discover undervalued companies
How is Tecan Group forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TECN's forecast earnings growth (13% per year) is above the savings rate (-0.3%).
Earnings vs Market: TECN's earnings (13% per year) are forecast to grow faster than the Swiss market (6.1% per year).
High Growth Earnings: TECN's earnings are forecast to grow, but not significantly.
Revenue vs Market: TECN's revenue (8% per year) is forecast to grow faster than the Swiss market (4.2% per year).
High Growth Revenue: TECN's revenue (8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TECN's Return on Equity is forecast to be low in 3 years time (12.4%).
Discover growth companies
How has Tecan Group performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TECN has high quality earnings.
Growing Profit Margin: TECN's current net profit margins (12.9%) are lower than last year (14.2%).
Past Earnings Growth Analysis
Earnings Trend: TECN's earnings have grown by 19% per year over the past 5 years.
Accelerating Growth: TECN's earnings growth over the past year (17.3%) is below its 5-year average (19% per year).
Earnings vs Industry: TECN earnings growth over the past year (17.3%) underperformed the Life Sciences industry 50.8%.
Return on Equity
High ROE: TECN's Return on Equity (9.9%) is considered low.
Discover strong past performing companies
How is Tecan Group's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: TECN's short term assets (CHF671.9M) exceed its short term liabilities (CHF306.4M).
Long Term Liabilities: TECN's short term assets (CHF671.9M) exceed its long term liabilities (CHF464.9M).
Debt to Equity History and Analysis
Debt Level: TECN's net debt to equity ratio (0.7%) is considered satisfactory.
Reducing Debt: TECN's debt to equity ratio has increased from 0.6% to 20.4% over the past 5 years.
Debt Coverage: TECN's debt is well covered by operating cash flow (67.9%).
Interest Coverage: TECN's interest payments on its debt are well covered by EBIT (35.9x coverage).
Discover healthy companies
What is Tecan Group current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: TECN's dividend (0.97%) isn’t notable compared to the bottom 25% of dividend payers in the Swiss market (1.99%).
High Dividend: TECN's dividend (0.97%) is low compared to the top 25% of dividend payers in the Swiss market (4.14%).
Stability and Growth of Payments
Stable Dividend: TECN is not paying a notable dividend for the Swiss market, therefore no need to check if payments are stable.
Growing Dividend: TECN is not paying a notable dividend for the Swiss market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: TECN is not paying a notable dividend for the Swiss market.
Cash Payout to Shareholders
Cash Flow Coverage: TECN is not paying a notable dividend for the Swiss market.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Achim von Leoprechting (53 yo)
Dr. Achim Von Leoprechting, Ph D., has been Chief Executive Officer of Tecan Group Ltd., since April 1, 2019. He had been Head of the Partnering Business division at Tecan Group Ltd.since October 1, 2013...
CEO Compensation Analysis
Compensation vs Market: Achim's total compensation ($USD3.29M) is above average for companies of similar size in the Swiss market ($USD1.84M).
Compensation vs Earnings: Achim's compensation has been consistent with company performance over the past year.
Experienced Management: TECN's management team is seasoned and experienced (6 years average tenure).
Experienced Board: TECN's board of directors are considered experienced (9.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.9%.
Tecan Group AG's employee growth, exchange listings and data sources
- Name: Tecan Group AG
- Ticker: TECN
- Exchange: SWX
- Founded: 1980
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CHF3.659b
- Shares outstanding: 12.72m
- Website: https://www.tecan.com
Number of Employees
- Tecan Group AG
- Seestrasse 103
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/27 00:00|
|End of Day Share Price||2022/06/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.